Clinical Trials Directory

Trials / Unknown

UnknownNCT05640921

Group-integrated Cognitive Behavioural Therapy (Gi-CBT) to Aid Communities' Reintegration of Former Terrorists in Nigeria: A Randomised Control Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
Teesside University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The project aims to make significant contributions that change the conversation in communities and policy circles through promoting knowledge of nonviolent peace strategies using the Group integrated Cognitive Behavioural Therapy (Gi-CBT) to help heal trauma, improve peace, and encourage positive rehabilitation and reintegration of former Boko Haram terrorists' members and their families.

Detailed description

The main question it aims to answer are: • What is the feasibility in terms of recruitment, retention, adherence to the intervention and communities/victims' satisfaction with Gi-CBT to promote healing and improve the successful reintegration of of former Boko Haram terrorists' members and their families.into society? Participants will be randomly allocated into two groups. The first group, the intervention group, will receive the Group integrated Cognitive Behavioural Therapy (Gi-CBT). The second group will receive government intervention involving media messages from the National Orientation Agency devoid of GiCBT. Researchers will compare Gi-CBT group with the media orientation group to see if there are differences between a change in attitude towards ex-offenders' reintegration at base line, end of intervention and three months follow up.

Conditions

Interventions

TypeNameDescription
BEHAVIORALGi-CBTGi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.
OTHERMedia OrientationThe MO sessions will embed media content to create awareness of the government's approaches to reintegration.

Timeline

Start date
2022-12-20
Primary completion
2023-11-30
Completion
2023-11-30
First posted
2022-12-07
Last updated
2022-12-07

Source: ClinicalTrials.gov record NCT05640921. Inclusion in this directory is not an endorsement.